Early activation of mTORC1 signalling in response to mechanical overload is independent of phosphoinositide 3-kinase/Akt signalling

Journal of Physiology

Volumn 589, Issue 7, 2011, Pages 1831-1846

  Miyazaki, Mitsunori ^a   Mccarthy, John J ^a   Fedele, Mark J ^b   Esser, Karyn A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROLINE RICH PROTEIN; PROTEIN KINASE B; RNA; SOMATOMEDIN C; TUBERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; IN VIVO STUDY; MECHANICAL STRESS; MUSCLE HYPERTROPHY; NONHUMAN; PLANTARIS MUSCLE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; RNA ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; HYPERTROPHY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; STRESS, MECHANICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79953152152     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2011.205658     Document Type: Article

References (52)

1. Adams GR & Haddad F (1996). The relationships among IGF-1, DNA content, and protein accumulation during skeletal muscle hypertrophy. J Appl Physiol 81, 2509-2516.
2. Adams GR, Haddad F & Baldwin KM (1999). Time course of changes in markers of myogenesis in overloaded rat skeletal muscles. J Appl Physiol 87, 1705-1712.
3. Adams GR & McCue SA (1998). Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol 84, 1716-1722.
4. Anjum R & Blenis J (2008). The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 9, 747-758.
5. Baar K & Esser K (1999). Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise. Am J Physiol Cell Physiol 276, C120-C127.
6. Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J & Gygi SP (2005). Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A 102, 667-672.
7. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ & Yancopoulos GD (2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3, 1014-1019.
8. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB & Schreiber SL (1995). Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377, 441-446.
9. Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr & Abraham RT (1997). Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99-101.
10. Daughaday WH & Rotwein P (1989). Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10, 68-91.
11. DeVol DL, Rotwein P, Sadow JL, Novakofski J & Bechtel PJ (1990). Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol Endocrinol Metab 259, E89-E95.
12. Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, Volpi E & Rasmussen BB (2009). Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. J Physiol 587, 1535-1546.
13. Duchene S, Audouin E, Crochet S, Duclos MJ, Dupont J & Tesseraud S (2008). Involvement of the ERK1/2 MAPK pathway in insulin-induced S6K1 activation in avian cells. Domest Anim Endocrinol 34, 63-73.
14. Fedele MJ, Vary TC & Farrell PA (2001). Selected contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats. J Appl Physiol 90, 1166-1173; discussion 1165.
15. Frost RA & Lang CH (2007). Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol 103, 378-387.
16. Glass DJ (2005). Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37, 1974-1984.
17. Goldberg AL (1967). Work-induced growth of skeletal muscle in normal and hypophysectomized rats. Am J Physiol 213, 1193-1198.
18. Goodman CA, Miu MH, Frey JW, Mabrey DM, Lincoln HC, Ge Y, Chen J & Hornberger TA (2010). A PI3K/PKB-independent activation of mTOR signaling is sufficient to induce skeletal muscle hypertrophy. Mol Biol Cell 21, 3258-3268.
19. Hambrecht R, Schulze PC, Gielen S, Linke A, Mobius-Winkler S, Erbs S, Kratzsch J, Schubert A, Adams V & Schuler G (2005). Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 12, 401-406.
20. Hornberger TA, Stuppard R, Conley KE, Fedele MJ, Fiorotto ML, Chin ER & Esser KA (2004). Mechanical stimuli regulate rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase B- and growth factor-independent mechanism. Biochem J 380, 795-804.
21. Horne Z & Hesketh J (1990). Immunological localization of ribosomes in striated rat muscle. Evidence for myofibrillar association and ontological changes in the subsarcolemmal:myofibrillar distribution. Biochem J 268, 231-236.
22. Huang J & Manning BD (2008). The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412, 179-190.
23. Inoki K, Li Y, Xu T & Guan KL (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17, 1829-1834.
24. Inoki K, Li Y, Zhu T, Wu J & Guan KL (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4, 648-657.
25. Isgaard J, Nilsson A, Vikman K & Isaksson OG (1989). Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J Endocrinol 120, 107-112.
26. Jacinto E & Hall MN (2003). Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4, 117-126.
27. Kubica N, Bolster DR, Farrell PA, Kimball SR & Jefferson LS (2005). Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2Be{open} mRNA in a mammalian target of rapamycin-dependent manner. J Biol Chem 280, 7570-7580.
28. Lai KM, Gonzalez M, Poueymirou WT, Kline WO, Na E, Zlotchenko E, Stitt TN, Economides AN, Yancopoulos GD & Glass DJ (2004). Conditional activation of Akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 24, 9295-9304.
29. Laplante M & Sabatini DM (2009). mTOR signaling at a glance. J Cell Sci 122, 3589-3594.
30. Ma L, Chen Z, Erdjument-Bromage H, Tempst P & Pandolfi PP (2005). Phosphorylation and functional inactivation of TSC2 by Erk. Cell 121, 179-193.
31. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C & Pandolfi PP (2007). Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67, 7106-7112.
32. McCarthy JJ & Esser KA (2007). MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 102, 306-313.
33. Matheny W, Merritt E, Zannikos SV, Farrar RP & Adamo ML (2009). Serum IGF-I-deficiency does not prevent compensatory skeletal muscle hypertrophy in resistance exercise. Exp Biol Med (Maywood) 234, 164-170.
34. Miyazaki M & Esser KA (2009a). Cellular mechanisms regulating protein synthesis and skeletal muscle hypertrophy in animals. J Appl Physiol 106, 1367-1373.
35. Miyazaki M & Esser KA (2009b). REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch. Am J Physiol Cell Physiol 296, C583-C592.
36. Miyazaki M, Hitomi Y, Kizaki T, Ohno H, Haga S & Takemasa T (2004). Contribution of the calcineurin signaling pathway to overload-induced skeletal muscle fiber-type transition. J Physiol Pharmacol 55, 751-764.
37. Miyazaki M, McCarthy JJ & Esser KA (2010). Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes. FEBS J 277, 2180-2191.
38. Nader GA & Esser KA (2001). Intracellular signaling specificity in skeletal muscle in response to different modes of exercise. J Appl Physiol 90, 1936-1942.
39. Nader GA, McLoughlin TJ & Esser KA (2005). mTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators. Am J Physiol Cell Physiol 289, C1457-C1465.
40. Novak ML, Billich W, Smith SM, Sukhija KB, McLoughlin TJ, Hornberger TA & Koh TJ (2009). COX-2 inhibitor reduces skeletal muscle hypertrophy in mice. Am J Physiol Regul Integr Comp Physiol 296, R1132-R1139.
41. O'Neil TK, Duffy LR, Frey JW & Hornberger TA (2009). The role of phosphoinositide 3-kinase and phosphatidic acid in the regulation of mammalian target of rapamycin following eccentric contractions. J Physiol 587, 3691-3701.
42. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma SC & Thomas G (2004). S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24, 3112-3124.
43. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD & Glass DJ (2001). Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3, 1009-1013.
44. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N & Blenis J (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282, 14056-14064.
45. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA & Sabatini DM (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25, 903-915.
46. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO & Ohlsson C (1999). Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 96, 7088-7092.
47. Spangenburg EE (2009). Changes in muscle mass with mechanical load: possible cellular mechanisms. Appl Physiol Nutr Metab 34, 328-335.
48. Spangenburg EE, Le Roith D, Ward CW & Bodine SC (2008). A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J Physiol 586, 283-291.
49. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J & Burgering BM (1998). Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 273, 13150-13156.
50. Vyas DR, Spangenburg EE, Abraha TW, Childs TE & Booth FW (2002). GSK-3β negatively regulates skeletal myotube hypertrophy. Am J Physiol Cell Physiol 283, C545-C551.
51. Witkowski S, Lovering RM & Spangenburg EE (2010). High-frequency electrically stimulated skeletal muscle contractions increase p70s6k phosphorylation independent of known IGF-I sensitive signaling pathways. FEBS Lett 584, 2891-2895.
52. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D (1999). Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96, 7324-7329.